| 查看: 254 | 回复: 0 | ||
西点6688木虫 (正式写手)
|
[求助]
各位大神，求助一段话的翻译，谢谢！~荟萃分析
|
|
RESULT We summarized 20 trials carried out in metastatic melanoma (MM), non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC) patients receiving anti-PD-1/PD-L1 antibodies (4230 MM, 1417 NSCLC and 312 RCC patients). Positive PD-L1 MM patients showed a significant decrease (53%) in the risk of mortality vs. negative cases with no heterogeneity. Furthermore, SORRs were 45% and 27% in PD-L1 positive and negative patients, respectively, and SOR indicates a significant difference in term of responses: 2.14 (95% CI: 1.65, 2.77), with low between-study heterogeneity (I2= 35%). Furthermore, results from randomized clinical trials on MM showed that PD-L1 expression is significantly associated with greater clinical response rates to anti-PD1 treatments (SOR 1.89; 95%CI: 1.35, 2.64) but not to other treatments (SOR 0.96; 95%CI: 0.5, 1.87). 因为是荟萃学分析，有些术语不理解，望专业人士点播，谢谢！原文网址： http://www.ncbi.nlm.nih.gov/pubmed/26895815 |
回复此楼» 猜你喜欢
硕博巨婴，也许才刚刚开始
已经有71人回复
-
初始合伙人来啦！（生物试剂耗材标准品）
已经有7人回复
-
杭电、天津科技、青农和宁波工程学院如何选？
已经有20人回复
-
34岁读博士晚吗
已经有26人回复
-
江西双非一本和四川双一流高校如何选择？
已经有23人回复
-
投稿被一个审稿人恶意评审了怎么样？
已经有7人回复
-
面青地会评时间
已经有5人回复
-
关于2023的收入
已经有34人回复
-
累并快乐着
已经有13人回复
-
每次骚扰女学生的都是院系领导，而不是普通教师，小编们要注意措辞正确
已经有9人回复
5